As a result, MYCN-amplified neuroblastoma cells are highly sensitive to inhibitors that block this metabolic pathway, suggesting that targeting SGOC metabolism may provide selective therapeutic benefits for patients with MYCN-amplified cancers [10, 11]. This evidence concerns the gene MYCN and neuroblastoma.